Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bo-Cheng Huang

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Pharmacological Research|February 6, 2022
Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesisKai-Wen Cheng, Chih-Hua Tseng, I-Ju Chen, et al.
Plos Biology|June 14, 2019
Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapyYun-Chi Lu, Chih-Hung Chuang, Kuo-Hsiang Chuang, et al.
Analytical Chemistry|May 10, 2017
Enhancement Effect of a Variable Topology of a Membrane-Tethered Anti-Poly(ethylene glycol) Antibody on the Sensitivity for Quantifying PEG and PEGylated MoleculesWen-Wei Lin, Yi-An Cheng, Chien-Han Kao, et al.
Bioengineering & Translational Medicine|October 1, 2025
Spatial-hindrance-based pro-Adalimumab prevents anti-idiotypic antibody interference in pharmacokinetic and therapeutic efficacyBo-Cheng Huang, Yu-Tung Chen, Yun-Chi Lu, et al.
International Journal of Biological Macromolecules|March 7, 2026
Engineering tumor-specific interferon-alpha-Nivolumab pro-immunocytokine for enhanced melanoma immunotherapyShi-Wei Chao, Bo-Cheng Huang, Shih-Ting Hong, et al.
Journal of Nanobiotechnology|February 1, 2022
A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodiesYuan-Chin Hsieh, Jun-Min Liao, Kuo-Hsiang Chuang, et al.
Scientific Reports|July 22, 2021
Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapyWen-Wei Lin, Yun-Chi Lu, Bo-Cheng Huang, et al.
NPJ Vaccines|November 20, 2025
To generate functional anti-protease-activated receptor-4 (PAR4), a G protein-coupled receptor, antibodies through PAR4-mRNA-LNP immunizationEn-Shuo Liu, Kai-Wen Ho, Chin-Chung Wu, et al.
International Journal of Biological Macromolecules|February 20, 2025
Development of a tumor-region-selective activation monoclonal antibody targeting the 4-1BB receptor for enhanced therapeutic efficacy and safetyTzu-Yi Liao, Yen-Ling Liu, Chiao-Yun Chen, et al.
International Journal of Biological Macromolecules|February 27, 2026
Selective activation of pro-anti-CTLA-4 antibody maintains therapeutic efficacy and reduces immune-related adverse eventsBo-Cheng Huang, Shih-Ting Hong, Tzu-Yi Liao, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Pharmacological Research|February 6, 2022
Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesisKai-Wen Cheng, Chih-Hua Tseng, I-Ju Chen, et al.
Plos Biology|June 14, 2019
Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapyYun-Chi Lu, Chih-Hung Chuang, Kuo-Hsiang Chuang, et al.
Analytical Chemistry|May 10, 2017
Enhancement Effect of a Variable Topology of a Membrane-Tethered Anti-Poly(ethylene glycol) Antibody on the Sensitivity for Quantifying PEG and PEGylated MoleculesWen-Wei Lin, Yi-An Cheng, Chien-Han Kao, et al.
Bioengineering & Translational Medicine|October 1, 2025
Spatial-hindrance-based pro-Adalimumab prevents anti-idiotypic antibody interference in pharmacokinetic and therapeutic efficacyBo-Cheng Huang, Yu-Tung Chen, Yun-Chi Lu, et al.
International Journal of Biological Macromolecules|March 7, 2026
Engineering tumor-specific interferon-alpha-Nivolumab pro-immunocytokine for enhanced melanoma immunotherapyShi-Wei Chao, Bo-Cheng Huang, Shih-Ting Hong, et al.
Journal of Nanobiotechnology|February 1, 2022
A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodiesYuan-Chin Hsieh, Jun-Min Liao, Kuo-Hsiang Chuang, et al.
Scientific Reports|July 22, 2021
Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapyWen-Wei Lin, Yun-Chi Lu, Bo-Cheng Huang, et al.
NPJ Vaccines|November 20, 2025
To generate functional anti-protease-activated receptor-4 (PAR4), a G protein-coupled receptor, antibodies through PAR4-mRNA-LNP immunizationEn-Shuo Liu, Kai-Wen Ho, Chin-Chung Wu, et al.
International Journal of Biological Macromolecules|February 20, 2025
Development of a tumor-region-selective activation monoclonal antibody targeting the 4-1BB receptor for enhanced therapeutic efficacy and safetyTzu-Yi Liao, Yen-Ling Liu, Chiao-Yun Chen, et al.
International Journal of Biological Macromolecules|February 27, 2026
Selective activation of pro-anti-CTLA-4 antibody maintains therapeutic efficacy and reduces immune-related adverse eventsBo-Cheng Huang, Shih-Ting Hong, Tzu-Yi Liao, et al.
Pageof 3